294 results on '"Mary Wu"'
Search Results
52. Simultaneous occurrence of idiopathic trachyonychia in dizygotic twins
- Author
-
Bibb, Lorin A., primary and Chang, Mary Wu, additional
- Published
- 2021
- Full Text
- View/download PDF
53. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study
- Author
-
Lisa Pickering, Nalinie Joharatnam-Hogan, Fiona Kinnaird, Andrew Furness, Mary Wu, Daqi Deng, Sina Namjou, Sarah Sarker, Aljosja Rogiers, Aida Murra, Justine Korteweg, Nicholas van As, Nicholas C. Turner, Anna Robinson, Joanne Droney, Kema Peat, Shaman Jhanji, Mike Gavrielides, Isla Leslie, Lauren Dowdie, Tara Foley, Christina Messiou, Natalie Ash, Taja Barber, Andrea Emslie-Henry, Simon Caidan, Karolina Rzeniewicz, Katalin A. Wilkinson, Ruth Harvey, Annika Fendler, Kate Tatham, Andreas M. Schmitt, Sunil Iyengar, Shreerang Bhide, Kayleigh Kelly, David L.V. Bauer, Benjamin Shum, Kim Edmonds, Gail Gardner, Scott Shepherd, Mark Ethell, Laura Amanda Boos, Liam Welsh, Robert J. Wilkinson, Lucy Holt, Alicia Okines, William Gordon, James I. MacRae, Maddalena Cerrone, Kevin J. Harrington, Mary Mangwende, Hamid Ahmod, Olivia Curtis, Emma Nicholson, Darren Murray, Susana Banerjee, Firza Gronthoud, Bhavna Oza, Naureen Starling, Wenyi Xie, Alison Reid, Karla Lingard, Ana Agua-Doce, Charles Swanton, Sacheen Kumar, Lewis Au, Michael Howell, James Larkin, Camille L. Gerard, Emma C Wall, Jessica Bazin, Ian Chau, Robin L. Jones, Fiona Byrne, Robyn L. Shea, Denise Kelly, Nadia Yousaf, Steve Gamblin, Kate Young, Sonia Gandhi, Susanna Walker, Eleanor Carlyle, Javier Pascual, David Cunningham, Samra Turajlic, Clemency Stephenson, Zayd Tippu, Gavin Kelly, Mary O'Brien, Sheima Farag, Molly O’Flaherty, George Kassiotis, Wanyuan Cui, Justin Mencel, Lyra Del Rosario, Simon Rodney, and Wellcome Trust
- Subjects
Male ,Cancer Research ,T-Lymphocytes ,Antibody Response ,Adaptive Immunity ,IMMUNOGENICITY ,Antibodies, Viral ,COVID-19 VACCINATION ,Immunogenicity, Vaccine ,Neoplasms ,Longitudinal Studies ,Prospective Studies ,Neutralizing antibody ,Prospective cohort study ,Cancer ,Aged, 80 and over ,Immunity, Cellular ,biology ,Vaccination ,Middle Aged ,Acquired immune system ,Kidney Neoplasms ,Oncology ,Female ,Antibody ,Life Sciences & Biomedicine ,Neutralising Antibodies ,T-cell Response ,Adult ,COVID-19 Vaccines ,Article ,MALIGNANCIES ,Crick COVID19 consortium ,Immunity ,VACCINES ,ChAdOx1 nCoV-19 ,medicine ,Humans ,Seroconversion ,Carcinoma, Renal Cell ,Pandemics ,BNT162 Vaccine ,Aged ,Science & Technology ,business.industry ,SARS-CoV-2 ,MORTALITY ,COVID-19 ,medicine.disease ,Antibodies, Neutralizing ,DEMOGRAPHICS ,Immunology ,biology.protein ,Prospective Study ,business ,Vaccine - Abstract
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.
- Published
- 2021
54. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
- Author
-
Edward J Carr, Mary Wu, Ruth Harvey, Emma C Wall, Gavin Kelly, Saira Hussain, Michael Howell, George Kassiotis, Charles Swanton, Sonia Gandhi, David LV Bauer, Roseanne E Billany, Matthew PM Graham-Brown, Joseph Beckett, Katherine Bull, Sushma Shankar, Scott Henderson, Reza Motallebzadeh, Alan D Salama, Lorraine Harper, Patrick B Mark, Stephen McAdoo, Michelle Willicombe, Rupert Beale, Sherna F Adenwalla, Paul Bird, Christopher Holmes, Katherine L Hull, Daniel S March, Haresh Selvaskandan, Jorge J Silva, Julian W Tang, Joanna Hester, Fadi Issa, Martin Barnardo, Peter J Friend, Andrew Davenport, Catriona Goodlad, Vignesh Gopalan, Theerasak Tangwonglert, Hans J Stauss, Alex G Richter, Adam F Cunningham, Marisol Perez-Toledo, Gemma D Banham, Nadya Wall, Candice L Clarke, Maria Prendecki, Bobbi Clayton, Sina Namjou, Vanessa Silva, Meghan Poulten, Philip Bawumia, Murad Miah, Samuel Sade, Mauro Miranda, Tom Taylor, Ilenia D'Angelo, Mercedes Cabrera Jarana, Mahbubur Rahman, Janet Abreu, Sandeep Sandhar, Neil Bailey, Simon Caidan, Marie Caulfield, Lorin Adams, Caitlin Kavanagh, Scott Warchal, Chelsea Sawyer, Mike Gavrielides, Jag Kandasamy, Karen Ambrose, Amy Strange, Titilayo Abiola, Nicola O'Reilly, Philip Hobson, Ana Agau-Doce, Emma Russell, Andrew Riddell, Svend Kjaer, Annabel Borg, Chloë Roustan, consortium, Haemodialysis COVID-19, and Pipeline, Crick COVID Immunity
- Subjects
Reino unido ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,biology ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Vaccination ,COVID-19 ,General Medicine ,Antibodies, Viral ,Virology ,Antibodies, Neutralizing ,United Kingdom ,Renal Dialysis ,Correspondence ,biology.protein ,Medicine ,Humans ,Antibody ,business - Abstract
No abstract available.
- Published
- 2021
55. 67 - Disorders of Hyperpigmentation
- Author
-
Weston, Gillian K. and Chang, Mary Wu
- Published
- 2025
- Full Text
- View/download PDF
56. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
- Author
-
Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorian Sopena, James MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, and Axel Behrens
- Subjects
Model organisms ,endocrine system diseases ,Immunology ,General Physics and Astronomy ,Gene Expression ,Infectious Disease ,Biochemistry & Proteomics ,General Biochemistry, Genetics and Molecular Biology ,Signalling & Oncogenes ,Mice ,Cell Line, Tumor ,Tumor Microenvironment ,Animals ,Humans ,Computational & Systems Biology ,Chemical Biology & High Throughput ,Human Biology & Physiology ,Multidisciplinary ,Stem Cells ,FOS: Clinical medicine ,Genome Integrity & Repair ,General Chemistry ,Cell Biology ,Tumour Biology ,digestive system diseases ,Pancreatic Neoplasms ,Metabolism ,Cardiovascular and Metabolic Diseases ,Genetics & Genomics ,Glycolysis ,Ubiquitin Thiolesterase ,Developmental Biology ,Carcinoma, Pancreatic Ductal - Abstract
Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential in pancreatic ductal adenocarcinoma (PDAC) has not been explored. Here, we develop a DUB discovery pipeline, combining activity-based proteomics with a loss-of-function genetic screen in patient-derived PDAC organoids and murine genetic models. This approach identifies USP25 as a master regulator of PDAC growth and maintenance. Genetic and pharmacological USP25 inhibition results in potent growth impairment in PDAC organoids, while normal pancreatic organoids are insensitive, and causes dramatic regression of patient-derived xenografts. Mechanistically, USP25 deubiquitinates and stabilizes the HIF-1α transcription factor. PDAC is characterized by a severely hypoxic microenvironment, and USP25 depletion abrogates HIF-1α transcriptional activity and impairs glycolysis, inducing PDAC cell death in the tumor hypoxic core. Thus, the USP25/HIF-1α axis is an essential mechanism of metabolic reprogramming and survival in PDAC, which can be therapeutically exploited.
- Published
- 2021
57. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- Author
-
Bryan Williams, Gavin Kelly, Mary Wu, Yenting Ngai, Vincenzo Libri, Saira Hussain, Ruth Harvey, Emine Hatipoglu, Andrew Riddell, Chelsea Sawyer, Rodney S. Daniels, Charles Swanton, Michael Howell, Philip Hobson, Karen Ambrose, Sonia Gandhi, Steve Hindmarsh, Robert J. Goldstone, Steve Gamblin, Emma C Wall, David L.V. Bauer, Rupert Beale, George Kassiotis, Jerome Nicod, and Scott Warchal
- Subjects
Adult ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Neutralising antibody ,General Medicine ,Biology ,Middle Aged ,Antibodies, Viral ,Virology ,Antibodies, Neutralizing ,Vaccination ,Correspondence ,biology.protein ,Humans ,Antibody ,BNT162 Vaccine - Published
- 2021
58. Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp12/7/8 RNA-dependent RNA Polymerase
- Author
-
Florian Weissmann, Berta Canal, Rachel Ulferts, Mary Wu, Michael Howell, John F.X. Diffley, Lucy S. Drury, Jennifer C. Milligan, Rupert Beale, Jingkun Zeng, Agustina P Bertolin, and Viktor Posse
- Subjects
0301 basic medicine ,viruses ,Drug Evaluation, Preclinical ,coronavirus ,Druggability ,Viral Nonstructural Proteins ,medicine.disease_cause ,RNA-dependent RNA polymerase ,Biochemistry ,Benzoates ,Chemical library ,chemistry.chemical_compound ,0302 clinical medicine ,RNA polymerase ,Chlorocebus aethiops ,Fluorescence Resonance Energy Transfer ,Research Articles ,Coronavirus ,chemistry.chemical_classification ,Coronavirus RNA-Dependent RNA Polymerase ,biology ,Small molecule ,Suramin ,Antiviral Agents ,Small Molecule Libraries ,03 medical and health sciences ,Biochemical Techniques & Resources ,Virology ,medicine ,Animals ,Molecular Biology ,Vero Cells ,Enzyme Assays ,SARS-CoV-2 ,Reproducibility of Results ,COVID-19 ,RNA virus ,Cell Biology ,Bridged Bicyclo Compounds, Heterocyclic ,biology.organism_classification ,High-Throughput Screening Assays ,nsp12 ,030104 developmental biology ,Enzyme ,Viral replication ,chemistry ,Holoenzymes ,030217 neurology & neurosurgery - Abstract
SummaryThe coronavirus disease 2019 (COVID-19) global pandemic has turned into the largest public health and economic crisis in recent history impacting virtually all sectors of society. There is a need for effective therapeutics to battle the ongoing pandemic. Repurposing existing drugs with known pharmacological safety profiles is a fast and cost-effective approach to identify novel treatments. The COVID-19 etiologic agent is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded positive-sense RNA virus. Coronaviruses rely on the enzymatic activity of the replication-transcription complex (RTC) to multiply inside host cells. The RTC core catalytic component is the RNA-dependent RNA polymerase (RdRp) holoenzyme. The RdRp is one of the key druggable targets for CoVs due to its essential role in viral replication, high degree of sequence and structural conservation and the lack of homologs in human cells. Here, we have expressed, purified and biochemically characterised active SARS-CoV-2 RdRp complexes. We developed a novel fluorescence resonance energy transfer (FRET)-based strand displacement assay for monitoring SARS-CoV-2 RdRp activity suitable for a high-throughput format. As part of a larger research project to identify inhibitors for all the enzymatic activities encoded by SARS-CoV-2, we used this assay to screen a custom chemical library of over 5000 approved and investigational compounds for novel SARS-CoV-2 RdRp inhibitors. We identified 3 novel compounds (GSK-650394, C646 and BH3I-1) and confirmed suramin and suramin-like compounds as in vitro SARS-CoV-2 RdRp activity inhibitors. We also characterised the antiviral efficacy of these drugs in cell-based assays that we developed to monitor SARS-CoV-2 growth.
- Published
- 2021
59. Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp3 Papain-like Protease
- Author
-
Mary Wu, Clovis Basier, George Papageorgiou, Michael Howell, Christelle Soudy, Theresa U. Zeisner, Rachel Ulferts, John F.X. Diffley, Chew Theng Lim, Dhira Joshi, Joseph F. Curran, Florian Weissmann, Hema Nagaraj, Tom D Deegan, Ryo Fujisawa, Berta Canal, Karim Labib, Kang Wei Tan, Ganka Bineva-Todd, Jennifer C. Milligan, and Rupert Beale
- Subjects
Protease ,Peptidomimetic ,viruses ,medicine.medical_treatment ,medicine.disease_cause ,Virology ,In vitro ,Chemical library ,chemistry.chemical_compound ,Papain ,chemistry ,Viral replication ,medicine ,Vero cell ,Coronavirus - Abstract
The coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5,000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activity in vitro, with IC50 values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC50. Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement.
- Published
- 2021
60. Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase
- Author
-
John W. McCauley, Ruth Harvey, Mary Wu, Laura E. McCoy, Agustina P Bertolin, Viktor Posse, Rupert Beale, Lucy S. Drury, John F.X. Diffley, Svend Kjaer, Saira Hussain, Berta Canal, Annabel Borg, Florian Weissmann, Jingkun Zeng, Jennifer C. Milligan, Rachel Ulferts, Michael Howell, and Chloe Roustan
- Subjects
0301 basic medicine ,viruses ,Drug Evaluation, Preclinical ,coronavirus ,Viral Nonstructural Proteins ,medicine.disease_cause ,Biochemistry ,Chemical library ,chemistry.chemical_compound ,0302 clinical medicine ,Chlorocebus aethiops ,Fluorescence Resonance Energy Transfer ,Research Articles ,media_common ,Coronavirus ,0303 health sciences ,biology ,030302 biochemistry & molecular biology ,RNA Helicase A ,Small molecule ,RNA Helicases ,Drug ,RNA helicase ,media_common.quotation_subject ,Suramin ,Antiviral Agents ,Virus ,Small Molecule Libraries ,03 medical and health sciences ,Biochemical Techniques & Resources ,Virology ,High-Throughput Screening Assays ,medicine ,Animals ,Molecular Biology ,Vero Cells ,Enzyme Assays ,030304 developmental biology ,SARS-CoV-2 ,Reproducibility of Results ,COVID-19 ,Helicase ,Cell Biology ,030104 developmental biology ,Viral replication ,chemistry ,nsp13 ,Vero cell ,biology.protein ,030217 neurology & neurosurgery - Abstract
SummaryThe coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global public health challenge. While the efficacy of vaccines against emerging and future virus variants remains unclear, there is a need for therapeutics. Repurposing existing drugs represents a promising and potentially rapid opportunity to find novel antivirals against SARS-CoV-2. The virus encodes at least nine enzymatic activities that are potential drug targets. Here we have expressed, purified and developed enzymatic assays for SARS-CoV-2 nsp13 helicase, a viral replication protein that is essential for the coronavirus life cycle. We screened a custom chemical library of over 5000 previously characterised pharmaceuticals for nsp13 inhibitors using a FRET-based high-throughput screening (HTS) approach. From this, we have identified FPA-124 and several suramin-related compounds as novel inhibitors of nsp13 helicase activity in vitro. We describe the efficacy of these drugs using assays we developed to monitor SARS-CoV-2 growth in Vero E6 cells.
- Published
- 2021
61. Identification of SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of the nsp14 RNA Cap Methyltransferase
- Author
-
Rachel Ulferts, Souradeep Basu, John F.X. Diffley, Tom D Deegan, Joseph F. Curran, Lucy S. Drury, Chew Theng Lim, Tiffany Mak, Ryo Fujisawa, Clovis Basier, Mary Wu, Karim Labib, Theresa U. Zeisner, Kang Wei Tan, Florian Weissmann, Victoria H. Cowling, Michael Howell, Rupert Beale, Allison W McClure, Emma A. Roberts, and Berta Canal
- Subjects
chemistry.chemical_classification ,Methyltransferase ,biology ,Viral protein ,RNA ,Translation (biology) ,biology.organism_classification ,medicine.disease_cause ,Virology ,Small molecule ,Enzyme ,Viral replication ,chemistry ,medicine ,Coronaviridae - Abstract
SummaryThe COVID-19 pandemic has presented itself as one of the most critical public health challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae family to cause fatal disease in humans. There is currently only one antiviral compound, remdesivir, that can be used for the treatment of COVID-19. In order to identify additional potential therapeutics, we investigated the enzymatic proteins encoded in the SARS-CoV-2 genome. In this study, we focussed on the viral RNA cap methyltransferases, which play a key role in enabling viral protein translation and facilitating viral escape from the immune system. We expressed and purified both the guanine-N7 methyltransferase nsp14, and the nsp16 2’-O-methyltransferase with its activating cofactor, nsp10. We performed an in vitro high-throughput screen for inhibitors of nsp14 using a custom compound library of over 5,000 pharmaceutical compounds that have previously been characterised in either clinical or basic research. We identified 4 compounds as potential inhibitors of nsp14, all of which also show antiviral capacity in a cell based model of SARS-CoV-2 infection. Three of the 4 compounds also exhibited synergistic effects on viral replication with remdesivir.
- Published
- 2021
62. Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of nsp5 Main Protease
- Author
-
Florian Weissmann, Chew Theng Lim, Clovis Basier, Christelle Soudy, Nicola O’Reilly, Karim Labib, Tom D Deegan, Ganka Bineva-Todd, Theresa U. Zeisner, Kang Wei Tan, Berta Canal, Rachel Ulferts, John F.X. Diffley, Dhira Joshi, Rupert Beale, Jennifer C. Milligan, Joseph F. Curran, George Papageorgiou, Michael Howell, Mary Wu, Ryo Fujisawa, and Hema Nagaraj
- Subjects
Azoles ,Leupeptins ,Peptidomimetic ,viruses ,medicine.medical_treatment ,Drug Evaluation, Preclinical ,coronavirus ,Isoindoles ,Viral Nonstructural Proteins ,medicine.disease_cause ,Biochemistry ,Amino Acid Chloromethyl Ketones ,Chemical library ,chemistry.chemical_compound ,0302 clinical medicine ,Organoselenium Compounds ,Chlorocebus aethiops ,nsp5 ,Fluorescence Resonance Energy Transfer ,Coronavirus 3C Proteases ,Research Articles ,Coronavirus ,0303 health sciences ,RNA-Binding Proteins ,Antiviral Agents ,Small Molecule Libraries ,03 medical and health sciences ,Biochemical Techniques & Resources ,Virology ,medicine ,Animals ,Vero Cells ,Molecular Biology ,Enzyme Assays ,030304 developmental biology ,Protease ,SARS-CoV-2 ,Leupeptin ,Reproducibility of Results ,COVID-19 ,protease ,Cell Biology ,In vitro ,High-Throughput Screening Assays ,Viral replication ,chemistry ,Vero cell ,Peptidomimetics ,030217 neurology & neurosurgery - Abstract
SummaryThe coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread around the world with unprecedented health and socio-economic effects for the global population. While different vaccines are now being made available, very few antiviral drugs have been approved. The main viral protease (nsp5) of SARS-CoV-2 provides an excellent target for antivirals, due to its essential and conserved function in the viral replication cycle. We have expressed, purified and developed assays for nsp5 protease activity. We screened the nsp5 protease against a custom chemical library of over 5,000 characterised pharmaceuticals. We identified calpain inhibitor I and three different peptidyl fluoromethylketones (FMK) as inhibitors of nsp5 activityin vitro, with IC50values in the low micromolar range. By altering the sequence of our peptidomimetic FMK inhibitors to better mimic the substrate sequence of nsp5, we generated an inhibitor with a subnanomolar IC50. Calpain inhibitor I inhibited viral infection in monkey-derived Vero E6 cells, with an EC50 in the low micromolar range. The most potent and commercially available peptidyl-FMK compound inhibited viral growth in Vero E6 cells to some extent, while our custom peptidyl FMK inhibitor offered a marked antiviral improvement.
- Published
- 2021
63. Multiple, familial, cellular neurothekeomas mimicking molluscum contagiosum: 301
- Author
-
Kelly, John, Kristjansson, Arni, Dadras, Soheil, and Chang, Mary Wu
- Published
- 2015
- Full Text
- View/download PDF
64. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
- Author
-
Svend Kjaer, Ruth Harvey, Rupert Beale, Saira Hussain, Catherine F Houlihan, Judith Heaney, Sonia Gandhi, Mary Wu, Eleni Nastouli, John W. McCauley, Hannah Rickman, Moira J. Spyer, Matthew Byott, Tulio de Oliveira, Rodney S. Daniels, Kevin W. Ng, Safer Investigators, Maria Greco, George Kassiotis, David L.V. Bauer, Daniel Frampton, Scott Warchal, William Bolland, Nikhil Faulkner, Marios Margaritis, Michael Howell, Stavroula Paraskevopoulou, Steve Gamblin, Alex Sigal, and Charles Swanton
- Subjects
2019-20 coronavirus outbreak ,biology ,Immunity ,Immunogenicity ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,biology.protein ,medicine ,Parental strain ,Antibody ,medicine.disease_cause ,Virology ,Cross-reactivity ,Neutralization - Abstract
We examined the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 that arose in the United Kingdom and spread globally. Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa B.1.351 variant, than of the infecting variant. The drop in cross-reactivity was more pronounced following B.1.1.7 than parental strain infection, indicating asymmetric heterotypic immunity induced by SARS-CoV-2 variants.
- Published
- 2021
65. Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy
- Author
-
Simona Balestrini, Matthias J. Koepp, Sonia Gandhi, Hannah M. Rickman, Gee Yen Shin, Catherine F. Houlihan, Jonny Anders-Cannon, Katri Silvennoinen, Fenglai Xiao, Sara Zagaglia, Kirsty Hudgell, Mariusz Ziomek, Paul Haimes, Adam Sampson, Annie Parker, J. Helen Cross, Rosemarie Pardington, Eleni Nastouli, Charles Swanton, Josemir W. Sander, Sanjay M. Sisodiya, Jim Aitken, Zoe Allen, Rachel Ambler, Karen Ambrose, Emma Ashton, Alida Avola, Samutheswari Balakrishnan, Caitlin Barns-Jenkins, Genevieve Barr, Sam Barrell, Souradeep Basu, Rupert Beale, Clare Beesley, Nisha Bhardwaj, Shahnaz Bibi, Ganka Bineva-Todd, Dhruva Biswas, Michael J. Blackman, Dominique Bonnet, Faye Bowker, Malgorzata Broncel, Claire Brooks, Michael D. Buck, Andrew Buckton, Timothy Budd, Alana Burrell, Louise Busby, Claudio Bussi, Simon Butterworth, Matthew Byott, Fiona Byrne, Richard Byrne, Simon Caidan, Joanna Campbell, Johnathan Canton, Ana Cardoso, Nick Carter, Luiz Carvalho, Raffaella Carzaniga, Natalie Chandler, Qu Chen, Peter Cherepanov, Laura Churchward, Graham Clark, Bobbi Clayton, Clementina Cobolli Gigli, Zena Collins, Sally Cottrell, Margaret Crawford, Laura Cubitt, Tom Cullup, Heledd Davies, Patrick Davis, Dara Davison, Vicky Dearing, Solene Debaisieux, Monica Diaz-Romero, Alison Dibbs, Jessica Diring, Paul C. Driscoll, Annalisa D'Avola, Christopher Earl, Amelia Edwards, Chris Ekin, Dimitrios Evangelopoulos, Rupert Faraway, Antony Fearns, Aaron Ferron, Efthymios Fidanis, Dan Fitz, James Fleming, Daniel Frampton, Bruno Frederico, Alessandra Gaiba, Anthony Gait, Steve Gamblin, Kathleen Gärtner, Liam Gaul, Helen M. Golding, Jacki Goldman, Robert Goldstone, Belen Gomez Dominguez, Hui Gong, Paul R. Grant, Maria Greco, Mariana Grobler, Anabel Guedan, Maximiliano G. Gutierrez, Fiona Hackett, Ross Hall, Steinar Halldorsson, Suzanne Harris, Sugera Hashim, Emine Hatipoglu, Lyn Healy, Judith Heaney, Susanne Herbst, Graeme Hewitt, Theresa Higgins, Steve Hindmarsh, Rajnika Hirani, Joshua Hope, Elizabeth Horton, Beth Hoskins, Michael Howell, Louise Howitt, Jacqueline Hoyle, Mint R. Htun, Michael Hubank, Hector Huerga Encabo, Deborah Hughes, Jane Hughes, Almaz Huseynova, Ming-Shih Hwang, Rachael Instrell, Deborah Jackson, Mariam Jamal-Hanjani, Lucy Jenkins, Ming Jiang, Mark Johnson, Leigh Jones, Nnennaya Kanu, George Kassiotis, Gavin Kelly, Louise Kiely, Anastacio King Spert Teixeira, Stuart Kirk, Svend Kjaer, Ellen Knuepfer, Nikita Komarov, Paul Kotzampaltiris, Konstantinos Kousis, Tammy Krylova, Ania Kucharska, Robyn Labrum, Catherine Lambe, Michelle Lappin, Stacey-Ann Lee, Andrew Levett, Lisa Levett, Marcel Levi, Hon Wing Liu, Sam Loughlin, Wei-Ting Lu, James I. MacRae, Akshay Madoo, Julie A. Marczak, Mimmi Martensson, Thomas Martinez, Bishara Marzook, John Matthews, Joachim M. Matz, Samuel McCall, Laura E. McCoy, Fiona McKay, Edel C. McNamara, Carlos M. Minutti, Gita Mistry, Miriam Molina-Arcas, Beatriz Montaner, Kylie Montgomery, Catherine Moore, David Moore, Anastasia Moraiti, Lucia Moreira-Teixeira, Joyita Mukherjee, Cristina Naceur-Lombardelli, Aileen Nelson, Jerome Nicod, Luke Nightingale, Stephanie Nofal, Paul Nurse, Savita Nutan, Caroline Oedekoven, Anne O'Garra, Jean D. O'Leary, Jessica Olsen, Olga O'Neill, Nicola O'Reilly, Paula Ordonez Suarez, Neil Osborne, Amar Pabari, Aleksandra Pajak, Venizelos Papayannopoulos, Stavroula M Paraskevopoulou, Namita Patel, Yogen Patel, Oana Paun, Nigel Peat, Laura Peces-Barba Castano, Ana Perez Caballero, Jimena Perez-Lloret, Magali S. Perrault, Abigail Perrin, Roy Poh, Enzo Z. Poirier, James M. Polke, Marc Pollitt, Lucia Prieto-Godino, Alize Proust, Clinda Puvirajasinghe, Christophe Queval, Vijaya Ramachandran, Abhinay Ramaprasad, Peter Ratcliffe, Laura Reed, Caetano Reis e Sousa, Kayleigh Richardson, Sophie Ridewood, Fiona Roberts, Rowenna Roberts, Angela Rodgers, Pablo Romero Clavijo, Annachiara Rosa, Alice Rossi, Chloe Roustan, Andrew Rowan, Erik Sahai, Aaron Sait, Katarzyna Sala, Emilie Sanchez, Theo Sanderson, Pierre Santucci, Fatima Sardar, Adam Sateriale, Jill A. Saunders, Chelsea Sawyer, Anja Schlott, Edina Schweighoffer, Sandra Segura-Bayona, Rajvee Shah Punatar, Maryam Shahmanesh, Joe Shaw, Mariana Silva Dos Santos, Margaux Silvestre, Matthew Singer, Daniel M. Snell, Ok-Ryul Song, Moira J. Spyer, Louisa Steel, Amy Strange, Adrienne E. Sullivan, Michele S.Y. Tan, Zoe H. Tautz-Davis, Effie Taylor, Gunes Taylor, Harriet B. Taylor, Alison Taylor-Beadling, Fernanda Teixeira Subtil, Berta Terré Torras, Patrick Toolan-Kerr, Francesca Torelli, Tea Toteva, Moritz Treeck, Hadija Trojer, Ming-Han C. Tsai, James M.A. Turner, Melanie Turner, Jernej Ule, Rachel Ulferts, Sharon P. Vanloo, Selvaraju Veeriah, Subramanian Venkatesan, Karen Vousden, Andreas Wack, Claire Walder, Philip A. Walker, Yiran Wang, Sophia Ward, Catharina Wenman, Luke Williams, Matthew J. Williams, Wai Keong Wong, Joshua Wright, Mary Wu, Lauren Wynne, Zheng Xiang, Melvyn Yap, Julian A. Zagalak, Davide Zecchin, Rachel Zillwood, Santhakumari Carthiyaniamma, Jane DeTisi, Julie Dick, Andrea Hill, Karin Kipper, Birinder Kullar, Sarah Norris, Fergus Rugg-Gunn, Rebecca Salvatierra, Gabriel Shaya, Astrid Sloan, Priyanka Singh, James Varley, Ben Whatley, and Academic Medical Center
- Subjects
Male ,Pediatrics ,CCC, Crick COVID Consortium ,SWGC, Sir William Gowers Centre ,Comorbidity ,Residential Facilities ,Cohort Studies ,Behavioral Neuroscience ,Epilepsy ,0302 clinical medicine ,Case fatality rate ,Infection control ,030212 general & internal medicine ,Care Models ,COVID-19, coronavirus disease 2019 ,Aged, 80 and over ,Surveillance ,Middle Aged ,3. Good health ,Treatment Outcome ,Neurology ,UCLH, University College London Hospitals NHS Foundation Trust ,PEG, percutaneous endoscopic gastrostomy ,STE, St Elizabeth’s Centre ,Female ,medicine.symptom ,PPE, personal protective equipment ,Cohort study ,Adult ,medicine.medical_specialty ,Isolation (health care) ,Clinical Neurology ,Asymptomatic ,Article ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,YE, Young Epilepsy ,Aged ,SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Infection Control ,business.industry ,SARS-CoV-2 ,Prevention ,Vulnerable people ,COVID-19 ,TM, The Meath ,medicine.disease ,Long-Term Care ,CCE, Chalfont Centre for Epilepsy ,United Kingdom ,Long-term care ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Contact tracing - Abstract
Highlights • We found a high asymptomatic rate in vulnerable people with epilepsy. • Enhanced surveillance allows to quickly contain outbreaks. • We report a low rate of COVID-19 morbidity and mortality in a long-term care facility. • Preventative measures allow reducing resident-to-resident and -to-caregiver transmission. • Children and young adults appear to have lower infection rates., In this cohort study, we aim to compare outcomes from coronavirus disease 2019 (COVID-19) in people with severe epilepsy and other co-morbidities living in long-term care facilities which all implemented early preventative measures, but different levels of surveillance. During 25-week observation period (16 March–6 September 2020), we included 404 residents (118 children), and 1643 caregivers. We compare strategies for infection prevention, control, and containment, and related outcomes, across four UK long-term care facilities. Strategies included early on-site enhancement of preventative and infection control measures, early identification and isolation of symptomatic cases, contact tracing, mass surveillance of asymptomatic cases and contacts. We measured infection rate among vulnerable people living in the facilities and their caregivers, with asymptomatic and symptomatic cases, including fatality rate. We report 38 individuals (17 residents) who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive, with outbreaks amongst residents in two facilities. At Chalfont Centre for Epilepsy (CCE), 10/98 residents tested positive: two symptomatic (one died), eight asymptomatic on weekly enhanced surveillance; 2/275 caregivers tested positive: one symptomatic, one asymptomatic. At St Elizabeth’s (STE), 7/146 residents tested positive: four symptomatic (one died), one positive during hospital admission for symptoms unrelated to COVID-19, two asymptomatic on one-off testing of all 146 residents; 106/601 symptomatic caregivers were tested, 13 positive. In addition, during two cycles of systematically testing all asymptomatic carers, four tested positive. At The Meath (TM), 8/80 residents were symptomatic but none tested; 26/250 caregivers were tested, two positive. At Young Epilepsy (YE), 8/80 children were tested, all negative; 22/517 caregivers were tested, one positive. Infection outbreaks in long-term care facilities for vulnerable people with epilepsy can be quickly contained, but only if asymptomatic individuals are identified through enhanced surveillance at resident and caregiver level. We observed a low rate of morbidity and mortality, which confirmed that preventative measures with isolation of suspected and confirmed COVID-19 residents can reduce resident-to-resident and resident-to-caregiver transmission. Children and young adults appear to have lower infection rates. Even in people with epilepsy and multiple co-morbidities, we observed a high percentage of asymptomatic people suggesting that epilepsy-related factors (anti-seizure medications and seizures) do not necessarily lead to poor outcomes.
- Published
- 2021
66. SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay
- Author
-
Jerome Nicod, James I. MacRae, Amin Oomatia, Laura Cubitt, Iana Martini, Simon Caidan, Kiran Gulati, Sonia Gandhi, Luke Nightingale, Michael D. Buck, Enzo Z. Poirier, Wei-Ting Lu, Margaret Crawford, Nicola O’Reilly, Amy Strange, Michael Howell, Steve Hindmarsh, Charles Swanton, Jessica Olsen, Samra Turajlic, George Kassiotis, Paul Grant, Rupert Beale, Caetano Reis e Sousa, Mary Wu, Ming Jiang, Robert L. Goldstone, Sam Barrell, Eleni Nastouli, Rachael Instrell, Bruno Frederico, Davin Miller, Anett Rideg, Ana Cardoso, Ok-Ryul Song, Johnathan Canton, Mike Hubank, David Moore, and Richard D. Byrne
- Subjects
0301 basic medicine ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030106 microbiology ,Medicine (miscellaneous) ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Pandemic ,Medicine ,Medical physics ,Viral rna ,Diagnostic laboratory ,Intensive care medicine ,License ,RT-LAMP ,business.industry ,SARS-CoV-2 ,Diagnostic test ,Creative commons ,Articles ,Method Article ,3. Good health ,030104 developmental biology ,business ,clinical diagnostic - Abstract
The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical research institute, in collaboration between partner hospitals and an accredited clinical diagnostic laboratory, established a diagnostic testing pipeline that has reported on more than 252,000 RT-qPCR results since its commencement at the beginning of April 2020. However, due to ongoing demand and competition for critical resources, alternative testing strategies were sought. In this work, we present a clinically-validated procedure for high-throughput SARSCoV-2 detection by RT-LAMP in 25 minutes that is robust, reliable, repeatable, sensitive, specific, and inexpensive © 2021. Buck MD et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Published
- 2021
67. Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome
- Author
-
Rachel Ulferts, William G. Scott, Yiliang Ding, Mary Wu, Nicole Doyle, Helena J. Maier, Felix Randow, Michal P. Wandel, Xiaofei Yang, Ben F. Luisi, Stephanie Oerum, Sara M. O'Rourke, Rupert Beale, Kotryna Bloznelyte, Valeria Lulla, Tom Dendooven, Katarzyna J Bandyra, Andrew E. Firth, Lulla, Valeria [0000-0002-6605-0727], Bandyra, Katarzyna [0000-0003-2607-6700], Firth, Andrew [0000-0002-7986-9520], Luisi, Ben [0000-0003-1144-9877], Apollo - University of Cambridge Repository, and Pfeiffer, Julie K
- Subjects
Untranslated region ,RNA Folding ,viruses ,coronavirus ,medicine.disease_cause ,Virus Replication ,Medical and Health Sciences ,Conserved sequence ,astrovirus ,0302 clinical medicine ,Chlorocebus aethiops ,Viral ,Replicon ,Lung ,Coronavirus ,Subgenomic mRNA ,Genetics ,s2m ,0303 health sciences ,Genome ,virus diseases ,gapmer ,Biological Sciences ,Stem-loop ,Infectious Diseases ,030220 oncology & carcinogenesis ,RNA, Viral ,Infection ,Biotechnology ,Immunology ,Genome, Viral ,Biology ,Microbiology ,Vaccine Related ,03 medical and health sciences ,Biodefense ,Virology ,Vaccines and Antiviral Agents ,medicine ,Animals ,Humans ,Nucleotide Motifs ,Vero Cells ,030304 developmental biology ,therapeutic oligonucleotides ,Agricultural and Veterinary Sciences ,SARS-CoV-2 ,Prevention ,plus-strand RNA virus ,RNA ,COVID-19 ,Pneumonia ,Emerging Infectious Diseases ,LNA ,HEK293 Cells ,Viral replication ,Insect Science - Abstract
RNA structural elements occur in numerous single-stranded positive-sense RNA viruses. The stem-loop 2 motif (s2m) is one such element with an unusually high degree of sequence conservation, being found in the 3' untranslated region (UTR) in the genomes of many astroviruses, some picornaviruses and noroviruses, and a variety of coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2. The evolutionary conservation and its occurrence in all viral subgenomic transcripts imply a key role for s2m in the viral infection cycle. Our findings indicate that the element, while stably folded, can nonetheless be invaded and remodeled spontaneously by antisense oligonucleotides (ASOs) that initiate pairing in exposed loops and trigger efficient sequence-specific RNA cleavage in reporter assays. ASOs also act to inhibit replication in an astrovirus replicon model system in a sequence-specific, dose-dependent manner and inhibit SARS-CoV-2 replication in cell culture. Our results thus permit us to suggest that the s2m element is readily targeted by ASOs, which show promise as antiviral agents. IMPORTANCE The highly conserved stem-loop 2 motif (s2m) is found in the genomes of many RNA viruses, including SARS-CoV-2. Our findings indicate that the s2m element can be targeted by antisense oligonucleotides. The antiviral potential of this element represents a promising start for further research into targeting conserved elements in RNA viruses.
- Published
- 2021
- Full Text
- View/download PDF
68. Hidradenitis Suppurativa
- Author
-
Jen, Melinda, primary and Chang, Mary Wu, additional
- Published
- 2013
- Full Text
- View/download PDF
69. Congenital Multiple Clustered Dermatofibroma in a 12-Year-Old Girl
- Author
-
Finch, Justin, Berke, Adrienne, Mccusker, Meagen, and Chang, Mary Wu
- Published
- 2014
- Full Text
- View/download PDF
70. Haptic Simulation of Elbow Joint Spasticity.
- Author
-
David I. Grow, Mengnan (Mary) Wu, Michael J. Locastro, Sugandha Arora, Amy J. Bastian, and Allison M. Okamura
- Published
- 2008
- Full Text
- View/download PDF
71. The stem loop 2 motif is a site of vulnerability for SARS-CoV-2
- Author
-
Kotryna Bloznelyte, Valeria Lulla, Xiaofei Yang, Sara M. O'Rourke, Ben F. Luisi, William G. Scott, Mary Wu, Felix Randow, Yiliang Ding, Rachel Ulferts, Nicole Doyle, Michal P. Wandel, Stephanie Oerum, Rupert Beale, Helena J. Maier, Tom Dendooven, Andrew E. Firth, and Katarzyna J Bandyra
- Subjects
Untranslated region ,viruses ,virus diseases ,RNA ,Replicon ,RNA Cleavage ,Biology ,biology.organism_classification ,Stem-loop ,Virology ,Astrovirus ,Conserved sequence ,Subgenomic mRNA - Abstract
SummaryRNA structural elements occur in numerous single stranded (+)-sense RNA viruses. The stemloop 2 motif (s2m) is one such element with an unusually high degree of sequence conservation, being found in the 3’ UTR in the genomes of many astroviruses, some picornaviruses and noroviruses, and a variety of coronaviruses, including SARS-CoV and SARS-CoV-2. The evolutionary conservation and its occurrence in all viral subgenomic transcripts implicates a key role of s2m in the viral infection cycle. Our findings indicate that the element, while stably folded, can nonetheless be invaded and remodelled spontaneously by antisense oligonucleotides (ASOs) that initiate pairing in exposed loops and trigger efficient sequence-specific RNA cleavage in reporter assays. ASOs also act to inhibit replication in an astrovirus replicon model system in a sequence-specific, dose-dependent manner and inhibit SARS-CoV-2 infection in cell culture. Our results thus permit us to suggest that the s2m element is a site of vulnerability readily targeted by ASOs, which show promise as anti-viral agents.
- Published
- 2020
72. Standard operating procedures for SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay
- Author
-
Kiran Gulati, Amy Strange, Laura Cubitt, Ana Cardoso, Charles Swanton, Jerome Nicod, Mike Hubank, Margaret Crawford, David Moore, James I. MacRae, Enzo Z. Poirier, Amin Oomatia, Simon Caidan, Eleni Nastouli, Robert J. Goldstone, Richard D. Byrne, Sam Barrell, Philip A. Walker, Wei-Ting Lu, Michael Howell, Caetano Reis e Sousa, Ming Jiang, Michael D. Buck, Steve Hindmarsh, Sonia Gandhi, Jessica Olsen, Davin Miller, Mary Wu, Anett Rideg, Steve Gamblin, Ok-Ryul Song, Rachael Instrell, George Kassiotis, Johnathan Canton, Paul Grant, Bruno Frederico, Nicola O’Reilly, Rupert Beale, Iana Martini, Luke Nightingale, and Samra Turajlic
- Subjects
medicine.medical_specialty ,business.industry ,Operating procedures ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Medicine ,Diagnostic test ,Medical physics ,Viral rna ,Diagnostic laboratory ,business ,Standard operating procedure - Abstract
The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical research institute, in collaboration between partner hospitals and an accredited clinical diagnostic laboratory, established a diagnostic testing pipeline that has reported on more than 40,000 RT-qPCR results since its commencement at the beginning of April 2020. However, due to ongoing demand and competition for critical resources, alternative testing strategies were sought. In this work, we present a clinically-validated standard operating procedure (SOP) for high-throughput SARS-CoV-2 detection by RT-LAMP in 25 minutes that is robust, reliable, repeatable, sensitive, specific, and inexpensive.
- Published
- 2020
73. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers
- Author
-
Catherine F Houlihan, Nina Vora, Thomas Byrne, Dan Lewer, Gavin Kelly, Judith Heaney, Sonia Gandhi, Moira J Spyer, Rupert Beale, Peter Cherepanov, David Moore, Richard Gilson, Steve Gamblin, George Kassiotis, Laura E McCoy, Charles Swanton, Andrew Hayward, Eleni Nastouli, Jim Aitken, Zoe Allen, Rachel Ambler, Karen Ambrose, Emma Ashton, Alida Avola, Samutheswari Balakrishnan, Caitlin Barns-Jenkins, Genevieve Barr, Sam Barrell, Souradeep Basu, Clare Beesley, Nisha Bhardwaj, Shahnaz Bibi, Ganka Bineva-Todd, Dhruva Biswas, Michael J Blackman, Dominique Bonnet, Faye Bowker, Malgorzata Broncel, Claire Brooks, Michael D Buck, Andrew Buckton, Timothy Budd, Alana Burrell, Louise Busby, Claudio Bussi, Simon Butterworth, Fiona Byrne, Richard Byrne, Simon Caidan, Joanna Campbell, Johnathan Canton, Ana Cardoso, Nick Carter, Luiz Carvalho, Raffaella Carzaniga, Natalie Chandler, Qu Chen, Laura Churchward, Graham Clark, Bobbi Clayton, Clementina Cobolli Gigli, Zena Collins, Sally Cottrell, Margaret Crawford, Laura Cubitt, Tom Cullup, Heledd Davies, Patrick Davis, Dara Davison, Annalisa D'Avola, Vicky Dearing, Solene Debaisieux, Monica Diaz-Romero, Alison Dibbs, Jessica Diring, Paul C Driscoll, Christopher Earl, Amelia Edwards, Chris Ekin, Dimitrios Evangelopoulos, Rupert Faraway, Antony Fearns, Aaron Ferron, Efthymios Fidanis, Dan Fitz, James Fleming, Bruno Frederico, Alessandra Gaiba, Anthony Gait, Liam Gaul, Helen M Golding, Jacki Goldman, Robert Goldstone, Belen Gomez Dominguez, Hui Gong, Paul R Grant, Maria Greco, Mariana Grobler, Anabel Guedan, Maximiliano G Gutierrez, Fiona Hackett, Ross Hall, Steinar Halldorsson, Suzanne Harris, Sugera Hashim, Lyn Healy, Susanne Herbst, Graeme Hewitt, Theresa Higgins, Steve Hindmarsh, Rajnika Hirani, Joshua Hope, Elizabeth Horton, Beth Hoskins, Michael Howell, Louise Howitt, Jacqueline Hoyle, Mint R Htun, Michael Hubank, Hector Huerga Encabo, Deborah Hughes, Jane Hughes, Almaz Huseynova, Ming-Shih Hwang, Rachael Instrell, Deborah Jackson, Mariam Jamal-Hanjani, Lucy Jenkins, Ming Jiang, Mark Johnson, Leigh Jones, Nnennaya Kanu, Louise Kiely, Anastacio King Spert Teixeira, Stuart Kirk, Svend Kjaer, Ellen Knuepfer, Nikita Komarov, Paul Kotzampaltiris, Konstantinos Kousis, Tammy Krylova, Ania Kucharska, Robyn Labrum, Catherine Lambe, Michelle Lappin, Stacey-Ann Lee, Andrew Levett, Lisa Levett, Marcel Levi, Hon-Wing Liu, Sam Loughlin, Wei-Ting Lu, James I MacRae, Akshay Madoo, Julie A Marczak, Mimmi Martensson, Thomas Martinez, Bishara Marzook, John Matthews, Joachim M Matz, Samuel McCall, Fiona McKay, Edel C McNamara, Carlos M Minutti, Gita Mistry, Miriam Molina-Arcas, Beatriz Montaner, Kylie Montgomery, Catherine Moore, Anastasia Moraiti, Lucia Moreira-Teixeira, Joyita Mukherjee, Cristina Naceur-Lombardelli, Aileen Nelson, Jerome Nicod, Luke Nightingale, Stephanie Nofal, Paul Nurse, Savita Nutan, Caroline Oedekoven, Anne O'Garra, Jean D O'Leary, Jessica Olsen, Olga O'Neill, Paula Ordonez Suarez, Nicola O'Reilly, Neil Osborne, Amar Pabari, Aleksandra Pajak, Venizelos Papayannopoulos, Namita Patel, Yogen Patel, Oana Paun, Nigel Peat, Laura Peces-Barba Castano, Ana Perez Caballero, Jimena Perez-Lloret, Magali S Perrault, Abigail Perrin, Roy Poh, Enzo Z Poirier, James M Polke, Marc Pollitt, Lucia Prieto-Godino, Alize Proust, Rajvee Shah Punatar, Clinda Puvirajasinghe, Christophe Queval, Vijaya Ramachandran, Abhinay Ramaprasad, Peter Ratcliffe, Laura Reed, Caetano Reis e Sousa, Kayleigh Richardson, Sophie Ridewood, Rowenna Roberts, Angela Rodgers, Pablo Romero Clavijo, Annachiara Rosa, Alice Rossi, Chloe Roustan, Andrew Rowan, Erik Sahai, Aaron Sait, Katarzyna Sala, Theo Sanderson, Pierre Santucci, Fatima Sardar, Adam Sateriale, Jill A Saunders, Chelsea Sawyer, Anja Schlott, Edina Schweighoffer, Sandra Segura-Bayona, Joe Shaw, Gee Yen Shin, Mariana Silva Dos Santos, Margaux Silvestre, Matthew Singer, Daniel M Snell, Ok-Ryul Song, Louisa Steel, Amy Strange, Adrienne E Sullivan, Michele SY Tan, Zoe H Tautz-Davis, Effie Taylor, Gunes Taylor, Harriet B Taylor, Alison Taylor-Beadling, Fernanda Teixeira Subtil, Berta Terré Torras, Patrick Toolan-Kerr, Francesca Torelli, Tea Toteva, Moritz Treeck, Hadija Trojer, Ming-Han C Tsai, James MA Turner, Melanie Turner, Jernej Ule, Rachel Ulferts, Sharon P Vanloo, Selvaraju Veeriah, Subramanian Venkatesan, Karen Vousden, Andreas Wack, Claire Walder, Philip A Walker, Yiran Wang, Sophia Ward, Catharina Wenman, Luke Wiliams, Matthew J Williams, Wai Keong Wong, Joshua Wright, Mary Wu, Lauren Wynne, Zheng Xiang, Melvyn Yap, Julian A Zagalak, Davide Zecchin, Rachel Zillwood, Rebecca Matthews, Abigail Severn, Sajida Adam, Louise Enfield, Angela McBride, Kathleen Gärtner, Sarah Edwards, Fabiana Lorencatto, Susan Michie, Ed Manley, Maryam Shahmanesh, Hinal Lukha, Paulina Prymas, Hazel McBain, Robert Shortman, Leigh Wood, Claudia Davies, Bethany Williams, Kevin W Ng, Georgina H Cornish, Nikhil Faulkner, Andrew Riddell, Philip Hobson, Ana Agua-Doce, Kerol Bartolovic, Emma Russell, Lotte Carr, Emilie Sanchez, Daniel Frampton, Matthew Byott, Stavroula M Paraskevopoulou, Elise Crayton, Carly Meyer, Triantafylia Gkouleli, Andrea Stoltenberg, Veronica Ranieri, Tom Byrne, Fiona Roberts, and Emine Hatipoglu
- Subjects
Adult ,2019-20 coronavirus outbreak ,Infectious Disease Transmission, Patient-to-Professional ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Health Personnel ,Pneumonia, Viral ,Viral transmission ,Antibodies, Viral ,Risk Assessment ,Article ,Betacoronavirus ,Environmental health ,Occupational Exposure ,Pandemic ,Health care ,London ,Medicine ,Humans ,Prospective Studies ,Seroconversion ,Pandemics ,Cross Infection ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Medicine ,Occupational exposure ,business ,Coronavirus Infections - Published
- 2020
74. Scalable and robust SARS-CoV-2 testing in an academic center
- Author
-
Jim, Aitken, Karen, Ambrose, Sam, Barrell, Rupert, Beale, Ganka, Bineva-Todd, Dhruva, Biswas, Richard, Byrne, Simon, Caidan, Peter, Cherepanov, Laura, Churchward, Graham, Clark, Margaret, Crawford, Laura, Cubitt, Vicky, Dearing, Christopher, Earl, Amelia, Edwards, Chris, Ekin, Efthymios, Fidanis, Alessandra, Gaiba, Steve, Gamblin, Sonia, Gandhi, Jacki, Goldman, Robert, Goldstone, Paul R, Grant, Maria, Greco, Judith, Heaney, Steve, Hindmarsh, Catherine F, Houlihan, Michael, Howell, Michael, Hubank, Deborah, Hughes, Rachael, Instrell, Deborah, Jackson, Mariam, Jamal-Hanjani, Ming, Jiang, Mark, Johnson, Leigh, Jones, Nnennaya, Kanu, George, Kassiotis, Stuart, Kirk, Svend, Kjaer, Andrew, Levett, Lisa, Levett, Marcel, Levi, Wei-Ting, Lu, James I, MacRae, John, Matthews, Laura E, McCoy, Catherine, Moore, David, Moore, Eleni, Nastouli, Jerome, Nicod, Luke, Nightingale, Jessica, Olsen, Nicola, O'Reilly, Amar, Pabari, Venizelos, Papayannopoulos, Namita, Patel, Nigel, Peat, Marc, Pollitt, Peter, Ratcliffe, Caetano, Reis E Sousa, Annachiara, Rosa, Rachel, Rosenthal, Chloe, Roustan, Andrew, Rowan, Gee Yen, Shin, Daniel M, Snell, Ok-Ryul, Song, Moira J, Spyer, Amy, Strange, Charles, Swanton, James M A, Turner, Melanie, Turner, Andreas, Wack, Philip A, Walker, Sophia, Ward, Wai Keong, Wong, Joshua, Wright, Mary, Wu, and Rachel, Zillwood
- Subjects
Europe ,COVID-19 Testing ,Medical research ,Clinical Laboratory Techniques ,Reverse Transcriptase Polymerase Chain Reaction ,Academies and Institutes ,Medical Laboratory Science ,Health care ,Humans ,Coronavirus Infections ,Author Correction ,United Kingdom - Published
- 2020
75. DA: Ecological and Evolutionary Inference Using Supervised Discriminant Analysis
- Author
-
T. Ryan Lock, Xinghu Qin, Mary Wu, and Robert L. Kallenbach
- Subjects
Structure (mathematical logic) ,Biological data ,Identification (information) ,Computer science ,Ecology ,Supervised learning ,Inference ,Evolutionary ecology ,Linear discriminant analysis ,Statistic - Abstract
With the rapid and large production of biological data (phenotypic traits, genomes, and simulated DNA), traditional statistic-based approaches may not meet the demands of ecological or evolutionary inferences. To mitigate this issue, we propose supervised visual and statistical machine learning approaches to do biological, evolutionary, and demographic inference. We introduce five supervised learning approaches (DAPC, DAKPC, LFDA, LFDAKPC, KLFDA) into ecology and evolution within the same discriminant analysis family, but with different linear and non-linear properties. We tested their performance and expected to find the optimal method for biological, evolutionary, and demographic inference. Applicable examples of such methods include species classification, population structure identification, and demography inference. We applied these five supervised learning techniques to simulated spatially-structured demographic scenarios along with realistic ecological and genetic data to elucidate their power and practicability in pattern inference. LFDA shows the highest discriminatory power in demographic inference. However, KLFDA outperforms other methods in population structure identification. DAPC and DAKPC differentiated species traits well when applied to real datasets. These approaches assess the structure of the data without model assumptions and show the potential to identify complex demographic histories and subtle population structure. We have made the DA package available at https://github.com/xinghuq/DA. We recommend users choose these machine learning approaches appropriately depending on their scientific questions and target data.
- Published
- 2020
76. Scalable and Resilient SARS-CoV-2 testing in an Academic Centre
- Author
-
Charles Swanton, James I. MacRae, Nnennaya Kanu, Steve Hindmarsh, Karen Ambrose, Andrew Levett, Judith Heaney, Maria Greco, Christopher Earl, Stuart Kirk, Rachel Instrell, Simon Caidan, Peter Cherepanov, Vicky Dearing, Wei-Ting Lu, Laura E. McCoy, George Kassiotis, Mary Wu, Amelia Edwards, Andrew Rowan, Michael Howell, Jessica Olsen, Venizelos Papayannopoulos, Amar Pabari, Caetano Reis e Sousa, Wai Keong Wong, Nicola O’Reilly, Marc Pollitt, Jerome Nicod, Philip A. Walker, Ming Jiang, Marg Crawford, Ganka Bineva-Todd, Alessandra Gaiba, Melanie Turner, Jacki Goldman, James M. A. Turner, Chloe Roustan, Sonia Gandhi, Catherine Moore, Nigel Peat, Rachel Rosenthal, John N. S. Matthews, Amy Strange, Chris Ekin, Marcel Levi, Richard D. Byrne, Laura Churchward, Steve Gamblin, Graham Clark, Jim Aitken, Deb Jackson, Mark Johnson, Svend Kjaer, Joshua Wright, Annachiara Rosa, Andreas Wack, Ok-Ryul Song, Laura Cubitt, Mariam Jamal-Hanjani, David Moore, Leigh Jones, Debbie Hughes, Paul Grant, Sophie Ward, Efthymios Fidanis, Namita Patel, Eleni Nastouli, Dhruva Biswas, Gee Yen Shin, Daniel M Snell, Mike Hubank, Lisa Levett, Moria Spyer, Peter J. Ratcliffe, Luke Nightingale, Sam Barrell, Rupert Beale, Robert L. Goldstone, and Catherine F Houlihan
- Subjects
0303 health sciences ,business.industry ,Computer science ,medicine.disease ,Pipeline (software) ,Turnaround time ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Health care ,Scalability ,Pandemic ,medicine ,Web application ,030212 general & internal medicine ,Medical emergency ,Diagnostic laboratory ,business ,Bespoke ,030304 developmental biology - Abstract
The emergence of the novel coronavirus SARS-CoV-2 has led to a pandemic infecting more than two million people worldwide in less than four months, posing a major threat to healthcare systems. This is compounded by the shortage of available tests causing numerous healthcare workers to unnecessarily self-isolate. We provide a roadmap instructing how a research institute can be repurposed in the midst of this crisis, in collaboration with partner hospitals and an established diagnostic laboratory, harnessing existing expertise in virus handling, robotics, PCR, and data science to derive a rapid, high throughput diagnostic testing pipeline for detecting SARS-CoV-2 in patients with suspected COVID-19. The pipeline is used to detect SARS-CoV-2 from combined nose-throat swabs and endotracheal secretions/ bronchoalveolar lavage fluid. Notably, it relies on a series of in-house buffers for virus inactivation and the extraction of viral RNA, thereby reducing the dependency on commercial suppliers at times of global shortage. We use a commercial RT-PCR assay, from BGI, and results are reported with a bespoke online web application that integrates with the healthcare digital system. This strategy facilitates the remote reporting of thousands of samples a day with a turnaround time of under 24 hours, universally applicable to laboratories worldwide.
- Published
- 2020
77. Walking With Ears: Altered Auditory Feedback Impacts Gait Step Length in Older Adults
- Author
-
Keith E. Gordon, Brennan Jackson, Jonathan H. Siegel, Sumitrajit Dhar, Tara Cornwell, Pamela E. Souza, Mengnan, Mary Wu, and Jane Woodward
- Subjects
medicine.medical_specialty ,Physiology ,Hearing loss ,Physical Therapy, Sports Therapy and Rehabilitation ,Audiology ,gait ,sound ,lcsh:GV557-1198.995 ,Medicine ,Orthopedics and Sports Medicine ,Ground reaction force ,Treadmill ,Balance (ability) ,Original Research ,Occlusion effect ,lcsh:Sports ,Auditory feedback ,business.industry ,Public Health, Environmental and Occupational Health ,balance ,Gait ,locomotion ,Sports and Active Living ,hearing ,Tourism, Leisure and Hospitality Management ,Anthropology ,Gait analysis ,medicine.symptom ,business - Abstract
Auditory feedback may provide the nervous system with valuable temporal (e. g., footstep sounds) and spatial (e.g., external reference sounds) information that can assist in the control of upright walking. As such, hearing loss may directly contribute to declines in mobility among older adults. Our purpose was to examine the impact of auditory feedback on the control of walking in older adults. Twenty older adults (65-86 years) with no diagnosed hearing loss walked on a treadmill for three sound conditions: Baseline, Ear Plugs, and White Noise. We hypothesized that in response to reduced temporal auditory feedback during the Ear Plugs and White Noise conditions, participants would adapt shorter and faster steps that are traditionally believed to increase mechanical stability. This hypothesis was not supported. Interestingly, we observed increases in step length (p = 0.047) and step time (p = 0.026) during the Ear Plugs condition vs. Baseline. Taking longer steps during the Ear Plugs condition may have increased ground reaction forces, thus allowing participants to sense footsteps via an occlusion effect. As a follow-up, we performed a Pearson's correlation relating the step length increase during the Ear Plugs condition to participants' scores on a clinical walking balance test, the Functional Gait Assessment. We found a moderate negative relationship (rho = -0.44, p = 0.055), indicating that participants with worse balance made the greatest increases in step length during the Ear Plugs condition. This trend suggests that participants may have actively sought auditory feedback with longer steps, sacrificing a more mechanically stable stepping pattern. We also hypothesized that reduced spatial localization feedback during the Ear Plugs and White Noise conditions would decrease control of center of mass (COM) dynamics, resulting in an increase in lateral COM excursion, lateral margin of stability, and maximum Lyapunov exponent. However, we found no main effects of auditory feedback on these metrics (p = 0.580, p = 0.896, and p = 0.056, respectively). Overall, these results suggest that during a steady-state walking task, healthy older adults can maintain walking control without auditory feedback. However, increases in step length observed during the Ear Plugs condition suggest that temporal auditory cues provide locomotor feedback that becomes increasingly valuable as balance deteriorates with age.
- Published
- 2020
78. The Spatial Genetic Structure Provides Insights into SARS-CoV-2 Recent Demographic History and Host Adaptation
- Author
-
Xinghu Qin and Mary Wu
- Published
- 2020
79. A Genetic Structure Map of SARS-CoV-2 from 62 Geographic Regions
- Author
-
Xinghu Qin and Mary Wu
- Subjects
Evolutionary biology ,fungi ,Genetic variation ,Genetic structure ,Outbreak ,Genome Scan ,Phylogenetic network ,Biology ,Adaptation ,skin and connective tissue diseases ,Gene ,Local adaptation - Abstract
Successive transmission of SARS-CoV-2 has caused a devastating influence on human health and the global economy. Previous studies have reported the origin, genetic mutation, phylogenetic network, etc., of SARS-CoV-2, since the first report of its outbreak in Wuhan. We presented the spatial genetic structure map of SARS-CoV-2, and further, revealed the genomic regions that were responsible for local adaptation. Spatial genetic variations of SARS-CoV-2 uncovered nuanced geographic clines across adjacent countries and also closely genetic relations between isolates from America, Canada, and Australia. Generally, SARS-CoV-2 isolates exhibited a significant genetic structure with several clusters showing strong genetic differentiation. Notably, one of the clusters was shared only among America, Canada, and Australia isolates, however, it was not found in the isolates of other geographic regions. Whole-genome scan showed that genomic regions of S, E, and M genes were strongly associated with adaptation. This study mirrors a snapshot of SARS-CoV-2 recent transmission and continual evolution on a local and global scale.
- Published
- 2020
80. Pityriasis Rubra Pilaris
- Author
-
Jen, Melinda, primary and Chang, Mary Wu, additional
- Published
- 2011
- Full Text
- View/download PDF
81. Translation, validation, and factor structure of the Nepali version of postpartum bonding questionnaires (PBQ-N) among postpartum women in Nepal.
- Author
-
Sangita Pudasainee-Kapri, Tumla Shrestha, Thomas Dahan, and Mary Wunnenberg
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
This study aimed to translate and test the psychometric properties of the Nepali version of the PBQ (PBQ-N) among postpartum mothers in Kathmandu, Nepal. Data was collected through semi-structured interviews with postpartum mothers (n = 128) of an infant aged one to six months visiting immunization clinics at two selected hospitals in Kathmandu, Nepal. The PBQ scale was translated into Nepali language and backtranslated to English with the help of language and content experts. The PBQ-N was then assessed for factor structure, validity, and reliability. The exploratory factor analysis (EFA) was conducted to examine construct validity of the PBQ-N in which 16 items (α = .75) of the original 25 items grouped into three subscales and were found suitable to measure mother-infant bonding among Nepalese women. Regarding convergent validity, a statistically significant, positive correlation was found between the PBQ-N and postpartum depression (r = .627, p < .001). In addition, a statistically significant, negative association was found between parenting self-efficacy and the PBQ-N (r = -.496, p < .001). The three subscales demonstrated good internal consistency. Findings indicate adequate estimates of validity and reliability for the PBQ-N in which 16-item measures were considered adequate for screening mother-infant bonding among Nepalese women and are useful for clinical and research purposes. Considering the crucial role of maternal-infant bonding relationships, the use of validated measures is recommended to screen high-risk infants in clinical settings.
- Published
- 2024
- Full Text
- View/download PDF
82. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. (Original Contribution)
- Author
-
Freedman, Abigail, Afonja, Olubunmi, Chang, Mary Wu, Mostashari, Farzad, Blaser, Martin, Perez-Perz, Guillermo, Lazarus, Herb, Schacht, Robert, Guttenberg, Jane, Traister, Michael, and Borkowsky, William
- Subjects
Anthrax -- Case studies ,Infants -- Diseases - Abstract
The case of a 7-month-old baby who developed anthrax from a skin exposure is presented. It is very unusual to develop internal symptoms from a skin exposure to anthrax. His symptoms lasted almost a month but he eventually recovered.
- Published
- 2002
83. Ecthyma Gangrenosum
- Author
-
Schaffer, Julie V., primary and Chang, Mary Wu, additional
- Published
- 2007
- Full Text
- View/download PDF
84. Contributors
- Author
-
Adams, David, primary, Adams, Sherri L., additional, Agarwal, Chhavi, additional, Alpern, Elizabeth R., additional, Matheny Antommaria, Armand H., additional, Bair-Merritt, Megan H., additional, Baptista-Neto, Lourival, additional, Baren, Jill, additional, Baum, Carl R., additional, Baum, Eric D., additional, Beasley, Pamela J., additional, Beno, Suzanne, additional, Bernard, Laurie A., additional, Bernstein, Stacey E., additional, Brands, Chad K., additional, Brennan, Laura K., additional, Brett-Fleegler, Marisa B., additional, Butte, Manish J., additional, Byerley, Julie Story, additional, Calello, Diane P., additional, Caplin, Deirdre, additional, Carlisle, Rebecca G., additional, Carlson, Douglas W., additional, Carroll, Jean Marie, additional, Chang, Mary Wu, additional, Cheng, Grace M., additional, Chidekel, Aaron S., additional, Chitkara, Denesh K., additional, Chiu, Bill, additional, Cho, Christine S., additional, Chow, Jeanne S., additional, Cilento, Bartley G., additional, Coffin, Susan E., additional, Cohen, Bernard A., additional, Cole, Kristina A., additional, Conway, Patrick H., additional, Cooper, Maura, additional, Cornell, Timothy, additional, Cronan, Kate M., additional, Cross, Catherine, additional, Cunningham, Bari B., additional, Cunningham, Melody J., additional, Daru, Jennifer A., additional, Davis, Ian J., additional, Deardorff, Matthew A., additional, Degar, Barbara, additional, DelVecchio, Michael, additional, DeMaso, David Ray, additional, Ungria, Marissa de, additional, Dewar, Stephanie B., additional, DeWolfe, Craig C., additional, Dimmers, Martha, additional, Dinulos, James G.H., additional, Donovan, Ed, additional, Dooley, Kenneth J., additional, Doyne, Emmanuel, additional, Duncan, Christine N., additional, Egan, Marie, additional, Eichenfield, Lawrence F., additional, El-hallak, Moussa, additional, Elisofon, Scott A., additional, Eppes, Stephen C., additional, Ewald, Michele Burns, additional, Farah, Mirna M., additional, Feudtner, Chris, additional, Fine, Andrew M., additional, Frangiskakis, Susan Hetzel, additional, Frank, Gary, additional, Frehm, Eric, additional, Frei, Nicole R., additional, Frieden, Ilona J., additional, Friedlaender, Eron Y., additional, Friedman, Jeremy, additional, Fryer, Robert Hugh, additional, Fulton, David R., additional, Galardy, Paul J., additional, Galashan, Mirabai, additional, Gallagher, Mary Pat, additional, Gamulka, Beth D., additional, Gandhi, Rupali, additional, Garza, Mary B., additional, Garzon, Maria C., additional, Geggel, Robert L., additional, Gewitz, Michael H., additional, Gibson, Timothy, additional, Gilliam, Amy E., additional, Ginnis, Katherine B., additional, Goldberg, Amy, additional, Golja, Anna M., additional, Gregory, Melissa J., additional, Harper, April A., additional, Harris, Mary Catherine, additional, Hayes, Natalie, additional, Heeney, Matthew M., additional, Heinzman, Diana M., additional, Heltzer, Meredith Lee, additional, Herzog, Keith D., additional, Hill, Malinda Ann, additional, Hills, Jessica L., additional, Hoberman, Alejandro, additional, Hoehn, K. Sarah, additional, Hoffman, Amber M., additional, Hoffman, Robert J., additional, Holst, Amy P., additional, Homer, Charles J., additional, Honig, Paul J., additional, Hopkins, Patricia M., additional, Hormann, Mark D., additional, Horn, B. David, additional, Isakoff, Michael S., additional, Janeway, Katherine A., additional, Jin, Katherine Ahn, additional, Jonas, Maureen M., additional, Kang, Tammy, additional, Keilty, Krista, additional, Keren, Ron, additional, Kharbanda, Anupam, additional, Kiesau, Marin, additional, Kim, Caroline C., additional, Kim, Jason Y., additional, Kim, Juliann Lipps, additional, Klein, Nicola, additional, Kleinman, Paul K., additional, Korin, Joel B., additional, Kotagal, Uma, additional, Kresnicka, Lisa K., additional, Kronfol, Rana N., additional, Kuelbs, Cynthia L., additional, Kugathasan, Subra, additional, Kurbegov, Amethyst C., additional, Landrigan, Christopher P., additional, Laufer, Miriam, additional, Lauren, Christine, additional, Lebovitz, Daniel J., additional, Leibel, Natasha, additional, Leung, Lucinda P., additional, Levine, Leonard J., additional, Levy, Jason A., additional, Lewis, Phyllis A., additional, Liang, Marilyn G., additional, Licht, Daniel J., additional, Long, Carolyn M., additional, Louie, Jeffrey P., additional, Love, Barry A., additional, Lowery, Patricia V., additional, MacLusky, Ian B., additional, Madejczyk, Katarzyna, additional, Madonna, Mary Beth, additional, Mahant, Sanjay, additional, Manicone, Paul E., additional, Maniscalco, Jennifer, additional, Mann, Keith, additional, Mannix, Rebekah, additional, Mansbach, Jonathan M., additional, Mattei, Peter, additional, Mayer, Oscar H., additional, McBride, Sarah C., additional, McBryde, Kevin D., additional, McKee, Michele R., additional, McNett, William, additional, Melzer, Sanford M., additional, Metjian, Talene A., additional, Metry, Denise W., additional, Muething, Stephen E., additional, Milliken, Emily E., additional, Mirkinson, Laura J., additional, Mittal, Manoj K., additional, Mix, Angela C., additional, Monzack, Debra, additional, Morel, Kimberly D., additional, Moses, Douglas E., additional, Mowad, Eugene M., additional, Mullen, Elizabeth A., additional, Mulliken, John B., additional, Muret-Wagstaff, Sharon, additional, Murphy, Nancy, additional, Nadel, Frances M., additional, Nagler, Joshua, additional, Nard, James A., additional, Neuman, Mark I., additional, Newland, Jason G., additional, Newton, Alice W., additional, Nichol, Peter F., additional, Nigrovic, Lise E., additional, Noel, Richard J., additional, Oberfield, Sharon E., additional, O'Brien, Maureen M., additional, O'Connell, Karen J., additional, Osterhoudt, Kevin C., additional, Ottolini, Mary, additional, Padman, Raj, additional, Padua, Horacio M., additional, Patel, Alka, additional, Pati, Susmita, additional, Percelay, Jack M., additional, Perez-Rossello, Jeannette M., additional, Phelan, Kieran J., additional, Poduri, Annapurna, additional, Poley, J. Rainer, additional, Posner, Jill C., additional, Prahalad, Sampath, additional, Pride, Howard B., additional, Rauch, Daniel, additional, Rawat, David J., additional, Reeves, Scott, additional, Reirden, Daniel H., additional, Roberts, Brandie J., additional, Rodgers, Jack, additional, Romero, José R., additional, Rosen, Paul, additional, Rubin, David M., additional, Sampayo, Esther Maria, additional, Samson-Fang, Lisa, additional, Santucci, Gina, additional, Schaffer, Julie V., additional, Schetzina, Karen E., additional, Schwab, Sandra, additional, Schwarz, Donald F., additional, Scott, Jordan, additional, Selbst, Steven M., additional, Shah, Kara N., additional, Shah, Samir S., additional, Shaikh, Nader, additional, Shannon, Michael W., additional, Sharma, Adhi N., additional, Siberry, George K., additional, Smith, Karen, additional, Smith, Michael J., additional, Somers, Michael J.G., additional, Sondheimer, Neal, additional, Spalding, Steven J., additional, Spandorfer, Philip R., additional, Spergel, Jonathan M., additional, Sperring, Jeffrey L., additional, Spiegel, David A., additional, Srivastava, Rajendu, additional, St. John, Keith H., additional, Stephens, Michael C., additional, Stewart, Christopher C., additional, Stone, Bryan L., additional, Stucky, Erin R., additional, Sundel, Eric R., additional, Sundel, Robert, additional, Swanson, Suzanne, additional, Taylor, Lesli, additional, Thompson, E. Douglas, additional, Traum, Avram Z., additional, Trivedi, Harsh K., additional, Upham, Bryan D., additional, Vandeven, Andrea M., additional, Vaughan, Brigid L., additional, Venditti, Charles P., additional, Villalva, Venus M., additional, Vincent, Robert N., additional, Volchenboum, Samuel, additional, Vossmeyer, Michael T., additional, Wachter, Robert M., additional, Weiner, Daniel J., additional, Weinstein, Michael, additional, Wharff, Elizabeth A., additional, Wilson, Stephen D., additional, Winkelstein, Jerry A., additional, Wolf, Heidi, additional, Woodward, George A., additional, Yan, Albert C., additional, Zackai, Elaine H., additional, Zaenglein, Andrea L., additional, Zaoutis, Theoklis E., additional, and Zipes, David, additional
- Published
- 2007
- Full Text
- View/download PDF
85. An Efficient Routing Protocol for Mobile Sinks in Sensor Networks
- Author
-
Mary Wu
- Subjects
Routing protocol ,Zone Routing Protocol ,Dynamic Source Routing ,business.industry ,Computer science ,Enhanced Interior Gateway Routing Protocol ,Wireless Routing Protocol ,020206 networking & telecommunications ,02 engineering and technology ,Link-state routing protocol ,Optimized Link State Routing Protocol ,0202 electrical engineering, electronic engineering, information engineering ,Mobile wireless sensor network ,020201 artificial intelligence & image processing ,business ,Computer network - Published
- 2017
86. Molecular diagnosis of a benign proliferative nodule developing in a congenital melanocytic nevus in a 3-month-old infant
- Author
-
Murphy, Michael J., Jen, Melinda, Chang, Mary Wu, Grant-Kels, Jane M., and Makkar, Hanspaul
- Published
- 2008
87. Effects of Haptic Feedback on Exploration.
- Author
-
Mengnan (Mary) Wu and Allison M. Okamura
- Published
- 2006
- Full Text
- View/download PDF
88. Confluent and Reticulated Papillomatosis Associated with Tinea Versicolor in Three Siblings
- Author
-
Stein, Jennifer A., Shin, Helen T., and Chang, Mary Wu
- Published
- 2005
89. Genetic Association of Cutaneous Neonatal Lupus With HLA Class II and Tumor Necrosis Factor α: Implications for Pathogenesis
- Author
-
Clancy, Robert M., Backer, Chelsea B., Yin, Xiaoming, Chang, Mary Wu, Cohen, Steven R., Lee, Lela A., and Buyon, Jill P.
- Published
- 2004
90. Infantile granular parakeratosis: Recognition of two clinical patterns
- Author
-
Chang, Mary Wu, Kaufmann, Julie M., Orlow, Seth J., Cohen, David E., Mobini, Narciss, and Kamino, Hideko
- Published
- 2004
91. Infantile systemic hyalinosis
- Author
-
Shin, Helen T., Paller, Amy, Hoganson, George, Willner, Judith P., Chang, Mary Wu, and Orlow, Seth J.
- Published
- 2004
92. Congenital Primary Cutaneous Rhabdomyosarcoma in a Neonate
- Author
-
Brecher, Alexandra R., Reyes-Mugica, Miguel, Kamino, Hideko, and Chang, Mary Wu
- Published
- 2003
93. 67 - Disorders of Hyperpigmentation
- Author
-
Chang, Mary Wu
- Published
- 2018
- Full Text
- View/download PDF
94. Berloque Dermatitis Mimicking Child Abuse
- Author
-
Gruson, Lisa Moed and Chang, Mary Wu
- Published
- 2002
95. Extensive Riga-Fede disease of the lip and tongue
- Author
-
Zaenglein, Andrea L., Chang, Mary Wu, Meehan, Shane A., Axelrod, Felicia B., and Orlow, Seth J.
- Published
- 2002
96. What Syndrome Is This?
- Author
-
Buddin, Deidre, Loomis, Cynthia, Shwayder, Tor, and Chang, Mary Wu
- Published
- 2002
97. Diagnosis and Treatment of Cutaneous Anthrax
- Author
-
Borkowsky, William and Chang, Mary Wu
- Published
- 2002
98. Cutaneous Anthrax Infection
- Author
-
Chang, Mary Wu, Roche, Kevin, and Lazarus, Herbert.
- Published
- 2002
99. Cutaneous Anthrax Infection
- Author
-
Roche, Kevin Joseph, Chang, Mary Wu, and Lazarus, Herbert.
- Published
- 2001
- Full Text
- View/download PDF
100. Cantharidin Revisited: A Blistering Defense of an Ancient Medicine
- Author
-
Moed, Lisa, Shwayder, Tor A., and Chang, Mary Wu
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.